Champions Biotechnology obtained patent rights encompassing two benzoylphenylurea (BPU) sulfur analog compounds that they report has shown potent activity against prostate and pancreatic cancer cell lines.
BPU is an antimitotic inhibitor that targets microtubule-associated protein tau deficient tumors, a common feature of solid tumors. These inhibitors have performed better than Docetaxel (Taxotere) in direct-patient xenograft models of pancreatic cancer, according to the company.
The company, in exchange for 550,000 restricted shares of its common stock, was assigned all the rights in the U.S. and in foreign countries to the applications for these inhibitors developed at Johns Hopkins University.